B·R·A·H·M·S PCT (Procalcitonin) Advancing the diagnosis of bacterial infection and antibiotic stewardship

Early diagnosis of patient infection improves their outcome, but also reduces unnecessary treatments and costs for healthcare facilities. To determine a patients’ appropriate antibiotic treatment, clinicians need data they can trust. This is why choosing a quality assay is so important.

With its sensitivity and specificity in identifying bacterial infections, combined with its fast kinetics, Thermo Scientific™ B·R·A·H·M·S PCT™ stands apart from other biomarkers.  

B·R·A·H·M·S PCT: When Quality Matters

Lab managers around the world face a common challenge: balancing the benefits of clinical application, assay quality, ease of implementation, and cost. Here’s how B·R·A·H·M·S PCT tests meet these criteria:

High sensitivity to detect the presence or absence of bacterial infection

B·R·A·H·M·S PCT is a highly sensitive assay that detects subtle increases in PCT, an indication of clinically relevant bacterial infections. 

Reference standard

B·R·A·H·M·S PCT assays were introduced from 1996 and used to establish the algorithm and clincal cut-offs for all of today's PCT clinical applications.

Safe and effective, as shown in 25 years of published clinical trials and studies

B·R·A·H·M·S PCT has been used to extensively investigate the clinical utility of procalcitonin for differential diagnosis, severity assessment, prognosis of bacterial infection, and antibiotic stewardship in studies around the world. The results of these studies have been featured in more than 7,000 publications.

Available on a wide range of laboratory platforms

B·R·A·H·M·S PCT is available on a wide range of major immunoassay analyzers, giving you the flexibility to choose the B·R·A·H·M·S PCT solution that best fits your lab’s needs.

Significant overall hospital savings with B·R·A·H·M·S PCT-aided care

B·R·A·H·M·S PCT can help clinicians optimize antibiotic prescription rates and tailor treatment duration to the individual patient’s needs. This approach improves patient outcomes but also shortens hospital stays and treatment duration, lowers the likelihood of antibiotic-associated adverse events, and reduces antibiotic resistance rates and healthcare costs.1-6

Helpful Links

Would you like to learn more about PCT?
Get a deeper understanding of PCT and it's role in antibiotic stewardship programs

Make sure you choose B·R·A·H·M·S PCT

The clinical and health economic benefits of PCT will only be achieved with quality assays that provide results equivalent to the clinical reference established with B·R·A·H·M·S PCT. Other PCT tests may claim to meet the clinical equivalence and safety standards of B·R·A·H·M·S PCT, but the evidence is lacking. For your patients, and your bottom line, choose B·R·A·H·M·S PCT.


Helpful Links

Let us help unlock the potential of B·R·A·H·M·S PCT in your hospital.
Contact Us.


Thermo Fisher Scientific products are distributed worldwide; not all intended uses and applications are registered in every country.

Availability of product in each country depends on local regulatory marketing authorization status.

References
  1. de Jong E, van Oers J, Beishuizen A, Vos P, Vermeijden W, Haas L, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. Lancet Infect Dis. 2016 Jul 1;16(7):819-27.
  2. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. Jama. 2009 Sep 9;302(10):1059-66.
  3. Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011 Dec;105(12):1939-45. 
  4. Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, Panagaki A, Melachroinopoulos N, Drakou E, Marousis K, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. a randomized trial. Amer J Resp Crit. 2021 Jan 15;203(2):202-10.
  5. Long W, Deng X, Zhang YU, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community‐acquired pneumonia. Respirology. 2011 Jul;16(5):819-24..
  6. Voermans AM, Mewes JC, Broyles MR, Steuten L. Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data. OMICS 2019 Oct;23(10):508-515. doi: 10.1089/omi.2019.0113.